Articles:

There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture

DD Von Hoff
Clin Cancer Res 1998 4: 1079 [Abstract] [PDF]  

New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions

PA Bunn, Jr and K Kelly
Clin Cancer Res 1998 4: 1087 [Abstract] [PDF]  

Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies

J Nemunaitis, C Poole, J Primrose, A Rosemurgy, J Malfetano, P Brown, A Berrington, A Cornish, K Lynch, H Rasmussen, D Kerr, D Cox, and A Millar
Clin Cancer Res 1998 4: 1101 [Abstract] [PDF]  

High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity

A Rasouli-Nia, D Liu, S Perdue, and RA Britten
Clin Cancer Res 1998 4: 1111 [Abstract] [PDF]  

Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2

KA Foon, G Sen, L Hutchins, OL Kashala, R Baral, M Banerjee, M Chakraborty, J Garrison, RA Reisfeld, and M Bhattacharya-Chatterjee
Clin Cancer Res 1998 4: 1117 [Abstract] [PDF]  

In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor

FM Uckun, RK Narla, T Zeren, Y Yanishevski, DE Myers, B Waurzyniak, O Ek, E Schneider, Y Messinger, LM Chelstrom, R Gunther, and W Evans
Clin Cancer Res 1998 4: 1125 [Abstract] [PDF]  

Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo

TL Whiteside, MW Sung, S Nagashima, K Chikamatsu, K Okada, and NL Vujanovic
Clin Cancer Res 1998 4: 1135 [Abstract] [PDF]  

Infrequent expression of p21 is related to altered p53 protein in pancreatic carcinoma

YX Hu, H Watanabe, K Ohtsubo, Y Yamaguchi, A Ha, Y Motoo, T Okai, and N Sawabu
Clin Cancer Res 1998 4: 1147 [Abstract] [PDF]  

Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors

CJ Gerrits, H Burris, JH Schellens, JR Eckardt, AS Planting, ME van der Burg, GI Rodriguez, WJ Loos, V van Beurden, I Hudson, S Fields, DD Von Hoff, and J Verweij
Clin Cancer Res 1998 4: 1153 [Abstract] [PDF]  

Phase I clinical trial of perillyl alcohol administered daily

GH Ripple, MN Gould, JA Stewart, KD Tutsch, RZ Arzoomanian, D Alberti, C Feierabend, M Pomplun, G Wilding, and HH Bailey
Clin Cancer Res 1998 4: 1159 [Abstract] [PDF]  

Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor

G Pizzorno, L Yee, BA Burtness, JC Marsh, JW Darnowski, MY Chu, SH Chu, E Chu, JJ Leffert, RE Handschumacher, and P Calabresi
Clin Cancer Res 1998 4: 1165 [Abstract] [PDF]  

In vivo native cellular fluorescence and histological characteristics of head and neck cancer

SP Schantz, V Kolli, HE Savage, G Yu, JP Shah, DE Harris, A Katz, RR Alfano, and AG Huvos
Clin Cancer Res 1998 4: 1177 [Abstract] [PDF]  

Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma

RJ Motzer, A Rakhit, LH Schwartz, T Olencki, TM Malone, K Sandstrom, R Nadeau, H Parmar, and R Bukowski
Clin Cancer Res 1998 4: 1183 [Abstract] [PDF]  

Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer

SM Tu, LC Pagliaro, ME Banks, RJ Amato, RE Millikan, NA Bugazia, T Madden, RA Newman, and CJ Logothetis
Clin Cancer Res 1998 4: 1193 [Abstract] [PDF]  

A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor

DF McDermott, EG Trehu, JW Mier, D Sorce, W Rand, L Ronayne, K Kappler, M Clancy, M Klempner, and MB Atkins
Clin Cancer Res 1998 4: 1203 [Abstract] [PDF]  

Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma

JF Eary, EU Conrad, JD Bruckner, A Folpe, KJ Hunt, DA Mankoff, and AT Howlett
Clin Cancer Res 1998 4: 1215 [Abstract] [PDF]  

Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers

D Morelli, D Lazzerini, S Cazzaniga, P Squicciarini, P Bignami, JA Maier, L Sfondrini, S Menard, MI Colnaghi, and A Balsari
Clin Cancer Res 1998 4: 1221 [Abstract] [PDF]  

p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site

HJ Lenz, KD Danenberg, CG Leichman, B Florentine, PG Johnston, S Groshen, L Zhou, YP Xiong, PV Danenberg, and LP Leichman
Clin Cancer Res 1998 4: 1227 [Abstract] [PDF]  

Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461

JC Byrd, D Lawrence, DC Arthur, MJ Pettenati, R Tantravahi, M Qumsiyeh, J Stamberg, FR Davey, CA Schiffer, and CD Bloomfield
Clin Cancer Res 1998 4: 1235 [Abstract] [PDF]  

p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival

HJ Lenz, K Hayashi, D Salonga, KD Danenberg, PV Danenberg, R Metzger, D Banerjee, JR Bertino, S Groshen, LP Leichman, and CG Leichman
Clin Cancer Res 1998 4: 1243 [Abstract] [PDF]  

Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers

FA Sinicrope, G Roddey, M Lemoine, S Ruan, LC Stephens, ML Frazier, Y Shen, and W Zhang
Clin Cancer Res 1998 4: 1251 [Abstract] [PDF]  

Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study)

DR Ciocca, S Green, RM Elledge, GM Clark, R Pugh, P Ravdin, D Lew, S Martino, and CK Osborne
Clin Cancer Res 1998 4: 1263 [Abstract] [PDF]  

Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network

P Lianes, E Charytonowicz, C Cordon-Cardo, Y Fradet, HB Grossman, GP Hemstreet, FM Waldman, K Chew, LL Wheeless, and D Faraggi
Clin Cancer Res 1998 4: 1267 [Abstract] [PDF]  

A similar pattern of chromosomal alterations in prostate cancers from African-Americans and Caucasian Americans

ML Cher, PE Lewis, M Banerjee, PM Hurley, W Sakr, DJ Grignon, and IJ Powell
Clin Cancer Res 1998 4: 1273 [Abstract] [PDF]  

Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer

H Kumar, K Heer, PW Lee, GS Duthie, AW MacDonald, J Greenman, MJ Kerin, and JR Monson
Clin Cancer Res 1998 4: 1279 [Abstract] [PDF]  

Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy

JL de Jong, NL Farner, BR Javorsky, MJ Lindstrom, JA Hank, and PM Sondel
Clin Cancer Res 1998 4: 1287 [Abstract] [PDF]  

Effect of immunosuppressive agents on the immunogenicity and efficacy of an immunotoxin in mice

EE Gelber and ES Vitetta
Clin Cancer Res 1998 4: 1297 [Abstract] [PDF]  

Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts

AM Al-Katib, MR Smith, WS Kamanda, GR Pettit, M Hamdan, AN Mohamed, B Chelladurai, and RM Mohammad
Clin Cancer Res 1998 4: 1305 [Abstract] [PDF]  

Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity

JF Ju, D Banerjee, HJ Lenz, KD Danenberg, TC Schmittgen, CP Spears, AH Schonthal, DJ Manno, D Hochhauser, JR Bertino, and PV Danenberg
Clin Cancer Res 1998 4: 1315 [Abstract] [PDF]  

Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro

C Aschele, C Baldo, AF Sobrero, D Debernardis, WG Bornmann, and JR Bertino
Clin Cancer Res 1998 4: 1323 [Abstract] [PDF]  

Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models

M Schirner, J Hoffmann, A Menrad, and MR Schneider
Clin Cancer Res 1998 4: 1331 [Abstract] [PDF]  

Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1

RM Mohammad, ML Varterasian, VP Almatchy, GN Hannoudi, GR Pettit, and A Al-Katib
Clin Cancer Res 1998 4: 1337 [Abstract] [PDF]  

Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines

CP Zou, JM Kurie, D Lotan, CC Zou, WK Hong, and R Lotan
Clin Cancer Res 1998 4: 1345 [Abstract] [PDF]  

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.